![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a (40 kD) induces HBeAg seroconversion/HBsAg loss in patients with HBeAg-positive chronic hepatitis B (The OSST study)
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Q Ning, M Han, Y Sun, J Jiang, D Tan, J Hou, H Tang, J Sheng,
M Zhao
Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China
![AASLD1.gif](../images/111912/111912-8/AASLD1.gif)
![AASLD2.gif](../images/111912/111912-8/AASLD2.gif)
![AASLD3.gif](../images/111912/111912-8/AASLD3.gif)
![AASLD4.gif](../images/111912/111912-8/AASLD4.gif)
![AASLD5.gif](../images/111912/111912-8/AASLD5.gif)
![AASLD6.gif](../images/111912/111912-8/AASLD6.gif)
![AASLD7.gif](../images/111912/111912-8/AASLD7.gif)
![AASLD8.gif](../images/111912/111912-8/AASLD8.gif)
![AASLD9.gif](../images/111912/111912-8/AASLD9.gif)
![AASLD10.gif](../images/111912/111912-8/AASLD10.gif)
![AASLD11.gif](../images/111912/111912-8/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|